Showing 5921-5930 of 6632 results for "".
- Mosquito Virus Expert Discusses a Promising New Drug For Zikahttps://practicaldermatology.com/news/mosquito-virus-expert-discusses-a-promising-new-drug-for-zika/2458257/Thomas Voss, PhD, a world-renowned leader in infectious disease research, and his team, say there are two strategies for developing a defense program against Zika infection: prevention, achieved by developing an effective vaccine and vaccination program or the development of a drug that can kill
- Pierre Fabre and Hill Dermaceuticals Partner in Commercial Partnership for TOLAK for AKshttps://practicaldermatology.com/news/pierre-fabre-and-hill-dermaceuticals-partner-in-commercial-partnership-for-tolak-for-aks/2458258/Pierre Fabre Dermo-Cosmetique and Hill Dermaceuticals, Inc. have entered into a strategic commercial partnership for TOLAK, a patented prescription dermatologic drug, indicated for the topical treatment of actinic keratosis lesions of the face, ears, and/or scalp. Under the terms of the a
- Cutanea Unveils Aktipak Gel, 3%/5%, Convenient Acne Treatment for "On-the-Go" Patientshttps://practicaldermatology.com/news/cutanea-unveils-aktipak-gel-35-convenient-acne-treatment-for-on-the-go-patients/2458260/Cutanea Life Sciences, Inc. (CLS) introduced Aktipak (erythromycin and benzoyl peroxide) Gel, 3%/5%, a combination therapy indicated for the topical treatment of acne vulgaris. The product is available through dermatologists' offices. Aktipak is a portable, freshly mixed, p
- Sun Pharma to Present Data from Tildrakizumab Clinical Development Program at 2017 AAD Meetinghttps://practicaldermatology.com/news/sun-pharma-to-present-data-from-tildrakizumab-clinical-development-program-at-2017-aad-meeting/2458266/Sun Pharmaceutical Industries Ltd will present several new analyses from Phase-1 and the pivotal Phase-3 clinical trials (reSURFACE 1 and 2) of tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis, at the 2017 Annual America
- BTL Aesthetics To Unveil New Ultra Femme 360° Technology for Vaginal Rejuvenation at AADhttps://practicaldermatology.com/news/btl-aesthetics-to-unveil-new-ultra-femme-360-technology-for-vaginal-rejuvenation-at-aad/2458263/BTL Industries is introducing its new 360° technology to leading cosmetic dermatologists and physicians during the annual American Academy of Dermatology (AAD) Conference taking place in Orlando, FL, March 3rd – 7th, with th
- Modernizing Medicine and Galderma Team Up to Offer Integrated OTC eCommerce Platformhttps://practicaldermatology.com/news/modernizing-medicine-and-galderma-team-up-to-offer-integrated-otc-ecommerce-platform/2458264/Specialty-specific health information technology company Modernizing Medicine, Inc. and Galderma Laboratories, L.P. are collaborating to deliver new capabilities in support of improved patient experiences and outcomes through healthcare provider recommended over-
- Skin Diseases Remain Major Cause of Disabilityhttps://practicaldermatology.com/news/skin-diseases-remain-major-cause-of-disability/2458267/Skin diseases are the fourth leading cause of disability worldwide, according to the Global Burden of Disease 2013 Study which appears online in JAMA Dermatology. For the study, researchers estimate
- Save The Dates: ASLMS to Host 37th Annual Conference In Early April 2017https://practicaldermatology.com/news/save-the-dates-aslms-to-host-37th-annual-conference-in-early-april-2017/2458279/American Society for Laser Medicine and Surgery (ASLMS) 2017 will take place April 5 – 9, 2017 in San Diego, Calif. New for 2017 is a special CME Session, Moving from the Lab to the Clinic, which will focus on the translation of technolog
- Researchers Discover New Antibiotic That May Fight MRSAhttps://practicaldermatology.com/news/researchers-discover-new-antibiotic-that-may-fight-mrsa/2458282/Researchers at the University of East Anglia (UEA) and the John Innes Centre (JIC) have uncovered a new antibiotic that they say is potent against antibiotic-resistant ‘superbugs’ like methicillin resistant Staphylococcus aureus (MRSA). The researchers isolated
- FDA Approves Valeant's SILIQ For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-valeants-siliq-for-moderate-to-severe-plaque-psoriasis/2458283/The FDA has approved the Biologics License Application (BLA) for Valeant Pharmaceutical's SILIQ (brodalumab) injection, for subcutaneous use, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis. SILIQ is indicated for the treatment of mo